Abstracts tagged "Anticardiolipin"

Abstract Number: 159 • 2018 ACR/ARHP Annual Meeting
The Frequency of Screening and Prevalence of Antiphospholipid Antibodies in the General Population
Giordano Egiziano¹, Jessica Widdifield², Anisur Rahman³, Evelyne Vinet⁴, Cristiano S. Moura⁵, Jeffrey R. Curtis⁶ and Sasha Bernatsky⁷, ¹Department Medicine, McGill University, Montreal, QC, Canada, ²University Health Network, Toronto, ON, Canada, ³Rayne Institute, University College London, London, United Kingdom, ⁴Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁵The Centre for Outcomes Research and Evaluation (CORE), McGill University Health Centre, Montreal, QC, Canada, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The antiphospholipid syndrome (APS) is defined by vascular thrombosis or pregnancy morbidity in the presence of persistently circulating antiphospholipid antibodies (aPL). Those positive for…
Abstract Number: 2628 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine and Prednisone Have Different Effects on Antiphospholipid Antibodies in SLE, with Hydroxychloroquine Not Reducing IgA Anticardiolipin
Michelle Petri¹, Mertcan Avci² and Laurence S Magder³, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Epidemiology and Public Health, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Antiphospholipid antibodies in SLE may be changed by treatment, but past studies have been conflicting. We examined the impact of starting or stopping two…
Abstract Number: 1060 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies and Related Clinical Events Following Infection in Children: A Systematic Review of Case Reports
Noha Abdel-Wahab¹, Maria A. Lopez-Olivo² and Maria Suarez-Almazor³, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Houston, TX, ²Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine,The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,, Houston, TX, ³Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: A systematic review of case reports to summarize existing evidence in the literature regarding the association of APS and infection during childhood. Our aims…
Abstract Number: 1065 • 2016 ACR/ARHP Annual Meeting
A Practical Application of Antiphospholipid Antibodies Profiles in the Diagnosis and Managements of Antiphospholipid Syndrome: The Modified Antiphospholipid Score
Kenji Oku¹, Olga Amengual², Kazumasa Ohmura¹, Masaru Kato³, Toshiyuki Bohgaki¹, Tetsuya Horita¹, Shinsuke Yasuda¹, Eriko Morishita⁴, Masahiro Ieko⁵ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Hokkaido University,Medicine II, Sapporo, Japan, ³Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁴College of Medical, Pharmaceutical and Health Science Kanazawa University, Kanazawa, Japan, ⁵Health Science University of Hokkaido, Toubetsu, Japan
Background/Purpose: The clinical scoring systems to quantify the probability for the diagnosis of antiphospholipid syndrome (APS) or future thrombosis, have been proposed as to reflect…
Abstract Number: 1066 • 2016 ACR/ARHP Annual Meeting
History of Lupus Nephritis Is an Independent Risk Factor for Thrombosis in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies
Vinicius Domingues¹, Janet Nwaukoni², Jill P. Buyon³ and H. Michael Belmont⁴, ¹Rheumatology, NYU Langone Medical Center, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Few studies have analyzed the risk factors for thrombosis in Systemic Lupus Erythematosus (SLE) patients with antiphospholipid antibodies (aPL) and most had small sample…
Abstract Number: 1067 • 2016 ACR/ARHP Annual Meeting
History of Thrombocytopenia Is Associated with Lower Prevalence of Thrombotic Events in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies
Vinicius Domingues¹, Janet Nwaukoni², Jill P. Buyon³ and H. Michael Belmont⁴, ¹Rheumatology, NYU Langone Medical Center, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Thrombocytopenia is a common feature of both systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) and in the former most frequently results from antiplatelet…
Abstract Number: 1964 • 2016 ACR/ARHP Annual Meeting
The Frequency and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibodies in Antiphospholipid Antibody Patients with and without Lupus
Ayten Yazici^1,2, OZAN UNLU³, Cecilia B. Chighizola⁴, Doruk Erkan⁵, Michelle Petri⁶ and On Behalf of APS ACTION .⁷, ¹Hospital for Special Surgery, Cornell Weill Cornell Medicine, NEW YORK CITY, NY, Turkey, ²Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, ³Rheumatology Department, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Department of Clinical Sciences and Community Health, University of Milan, IRCCS Istituto Auxologico Italiano, Milano, Italy, ⁵Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁶Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷., New York, NY
Background/Purpose: APS ACTION International Clinical Database and Repository was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive…
Abstract Number: 2004 • 2015 ACR/ARHP Annual Meeting
Procoagulant Property of a Novel Patient-Derived Autoimmune IgG Type Monoclonal Anticardiolipin Antibody That Binds to Beta 2 Glycoprotein Domain I but Not to Total Beta 2 Glycoprotein I Molecule
Kenji Oku¹, Yusaku Kanetsuka¹, Olga Amengual¹, Hiroyuki Nakamura¹, Kazumasa Oomura¹, Toshiyuki Bohgaki², Tetsuya Horita¹, Shinsuke Yasuda¹, Bas deLaat³ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Department of Biochemistry, Cardiovascular research Institute Maastricht, Maastricht University, Maastricht, Netherlands
Background/Purpose: Anti-cardiolipin/β2 glycoprotein I (aCL/β2GPI) antibodies are representative antiphospholipid antibodies(aPLs) that target the complex of cardiolipin (or anionic molecules) and β2GPI. However, aCL is often regarded…
Abstract Number: 2185 • 2015 ACR/ARHP Annual Meeting
Small but Clinically Insignificant Decreases in Antiphospholipid Antibody Titers Occur in aPL-Positive Patients during Pregnancy
Cécile Yelnik^1,2, Flint Porter^3,4, Ware D. Branch^3,4, Jill P. Buyon⁵, Marta Guerra⁶, Carl Laskin⁷, Michael Lockshin⁸, Michelle Petri⁹, Joan T. Merrill¹⁰, Lisa R. Sammaritano¹¹, Mary D. Stephenson¹², Mimi Y. Kim¹³ and Jane E. Salmon^11,14, ¹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ²Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ³University of Utah, Salt Lake City, UT, ⁴Intermountain Healthcare, Salt Lake City, UT, ⁵NYU School of Medicine, New York, NY, ⁶Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ⁷Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁸Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY, ⁹Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rheumatology, Hospital for Special Surgery, New York, NY, ¹²University of Illinois College of Medicine, Chicago, IL, ¹³Albert Einstein College of Medicine, Bronx, NY, ¹⁴Hospital for Special Surgery, New York, NY
Background/Purpose: The presence of aPL has been associated with pregnancy complications, but the evolution of aPL titers during pregnancy in aPL-positive patients and the utility…
Abstract Number: 2190 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratory Validation Exercise: Comparison of Enzyme-Linked Immunosorbant Assay (ELISA) and Chemiluminescence Immunoassay (CIA)
Maria Laura Bertolaccini¹, Danieli Andrade², Gabriella Lakos³, Rohan Willis⁴, Vittorio Pengo⁵, Alessandra Banzato⁶, Hannah Cohen⁷, Steven Krilis⁸, Doruk Erkan⁹ and on behalf of APS ACTION, ¹Lupus Unit, Rayne Institute, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ²Rheumatology, University of São Paulo, São Paulo, Brazil, ³INOVA Diagnostics, Inc., San Diego, CA, ⁴Department of Internal Medicine, Antiphospholipid Standardization Laboratory, Division of Rheumatology, Galveston, TX, ⁵Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, ⁶Department of Cardiac Thoracic and Vascular Sciences, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ⁷Hematology., University College London, LOndon, United Kingdom, ⁸Immunology, Allergy, and Infectious Diseases, St George Hospital, Kogarah NSW, Australia, ⁹Rheumatology, Barbara Volcker Center for Women and Rheumatic Diseases: Hospital for Special Surgery, New York, NY
Background/Purpose: APS ACTION International Clinical Database and Repository was created to study the natural course of disease over 10 years in persistently aPL-positive patients with/without…
Abstract Number: 2868 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Initial Analysis
Doruk Erkan¹, Danieli Andrade², Maria Tektonidou³, Amaia Ugarte⁴, Alessandra Banzato⁵, Angela Tincani⁶, Pier-Luigi Meroni⁷, Ricard Cervera⁸, Paul R. Fortin⁹, Roger A. Levy¹⁰ and On Behalf of APS Action¹¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, University of São Paulo, São Paulo, Brazil, ³First Department of Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ⁴Hospital Universitario Cruces, Bizkaia, Spain, ⁵Department of Cardiac Thoracic and Vascular Sciences, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ⁶Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁷Int Medicine, University of Milan, Milano, Italy, ⁸Hospital Clinic, Barcelona, Spain, ⁹Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada, ¹⁰Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹¹APS ACTION, New York, NY
Background/Purpose: APS ACTION International Clinical Database and Repository (“Registry”) was created to study the natural course of disease over 10 years in persistently aPL-positive patients…
Abstract Number: 2162 • 2014 ACR/ARHP Annual Meeting
Immunological Abnormalities in Adult Patients with Parvovirus B19 Infection : A study of 23 Cases
Edouard Pertuiset, Farid Kemiche, Mehdi Yahia and Isabelle Cerf-Payrastre, Rheumatology, Centre Hospitalier René Dubos, Pontoise, France
Background/Purpose In adults, parvovirus B19 infection can induce joint symptoms and cutaneous manifestations which are known to be transient most of the time. It has…
Abstract Number: 970 • 2014 ACR/ARHP Annual Meeting
Risk of Developing Antiphospholipid Syndrome Following Infection: A Systematic Review and Meta-Analysis of Observational Studies
Noha Abdel-Wahab^1,2, Maria A. Lopez-Olivo³, Saurabh Talathi⁴ and Maria E. Suarez-Almazor¹, ¹The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Rheumatology & Rehabilitation Department, Assiut University Hospital, Assiut, Egypt, ³Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas Health Science Center at Houston, School of Public Health, Houston, TX
Background/Purpose: Infection has been increasingly reported in the literature as an environmental trigger inducing the development of anti-phospholipid antibodies or antiphospholipid syndrome in genetically predisposed…
Abstract Number: 17 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Following Infection: A Systematic Review of Case Reports
Noha Abdel-Wahab^1,2, Maria A. Lopez-Olivo³, Paola Patarroyo-Pinto⁴ and Maria E. Suarez-Almazor², ¹Rheumatology & Rehabilitation Department, Assiut University Hospital, Assiut, Egypt, ²The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴Baylor College of Medicine, Houston, TX
Background/Purpose The occurrence of antiphospholipid syndrome (APS) following an infection has been increasingly reported in the literature. We conducted a systematic review of case reports…
Abstract Number: 19 • 2013 ACR/ARHP Annual Meeting
Association Of Antiphospholipid Antibodied Detected In The Aphl ELISA With Clinical Manifestations Of The Antiphospholipid Syndrome In Two Lupus Cohorts
Silvia S. Pierangeli¹, Rohan Willis², Michelle Petri³, Hong Fang⁴, Monica Smikle⁵, Karel de Ceulaer⁶ and E. Nigel Harris⁷, ¹Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Int Medicine/Rheumatology, University of Texas Medical Branch, Galveston, TX, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Microbiology, University of the West Indies, Kgn 7, Jamaica, ⁶Microbiology, University of the West Indies, KIngston, Jamaica, ⁷Office of the Vice Chancellor, The University of the West Ind, Kingston, Jamaica
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipid (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].